Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

121. Psychological effects of advanced nursing care (ANC) for patients with lung cancer (LC) post surgery: a systematic review

Psychological effects of advanced nursing care (ANC) for patients with lung cancer (LC) post surgery: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

122. Prognostic value of idiopathic pulmonary fibrosis in lung cancer: a systematic review and meta-analysis

Prognostic value of idiopathic pulmonary fibrosis in lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

123. Prognostic significance of preoperative neutrophil/lymphocyte ratio (NLR) in patients with resectable non-small cell lung cancer: a meta-analysis

Prognostic significance of preoperative neutrophil/lymphocyte ratio (NLR) in patients with resectable non-small cell lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

124. Comparative efficacy and safety between tivantinib plus erlotinib and erlotinib plus placebo in patients with previously treated stage IIIb/IV non-small-cell lung cancer: a meta-analysis based on randomized controlled trials

Comparative efficacy and safety between tivantinib plus erlotinib and erlotinib plus placebo in patients with previously treated stage IIIb/IV non-small-cell lung cancer: a meta-analysis based on randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate

2019 PROSPERO

125. Clinical utility of lymphocyte-to-monocyte ratio in lung cancer: a meta-analysis

Clinical utility of lymphocyte-to-monocyte ratio in lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

126. Association of survival with atezolizumab for patients with previously treated advanced non-small-cell lung cancer without EGFR and ALK mutations: results from two phase 2/3 randomised controlled trials

Association of survival with atezolizumab for patients with previously treated advanced non-small-cell lung cancer without EGFR and ALK mutations: results from two phase 2/3 randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

127. Application of CT, PET-CT, MRI, EBUS and mediastinoscopy in the diagnosis of mediastinal lymph node staging of non-small-cell lung cancer: a meta-analysis

Application of CT, PET-CT, MRI, EBUS and mediastinoscopy in the diagnosis of mediastinal lymph node staging of non-small-cell lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

128. The efficacy and safety of anlotinib as a third-line or further treatment for patients with advanced non-small cell lung cancer: a meta-analysis

The efficacy and safety of anlotinib as a third-line or further treatment for patients with advanced non-small cell lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

129. Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: an updated systematic review and meta-analysis

Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: an updated systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

130. Efficacy and safety of anlotinib versus osimertinib as a potential third-line or further-line treatment for patients with non-small-cell lung cancer (NSCLC) in China - a systematic review and meta-analysis

Efficacy and safety of anlotinib versus osimertinib as a potential third-line or further-line treatment for patients with non-small-cell lung cancer (NSCLC) in China - a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

131. Evaluating PD1 and PDL1 immunotherapy for the management of non-small cell lung cancer

Evaluating PD1 and PDL1 immunotherapy for the management of non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

132. Effects of high quality nursing care for patients with lung cancer during perioperative period: a protocol of systematic review of randomized controlled trials

Effects of high quality nursing care for patients with lung cancer during perioperative period: a protocol of systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

133. Effectiveness of smoking cessation in high-risk population by early screening of lung cancer: a systematic review and meta-analysis of randomised controlled trials

Effectiveness of smoking cessation in high-risk population by early screening of lung cancer: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

134. Compound kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: a meta-analysis of 37 RCTs following the PRISMA guidelines

Compound kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: a meta-analysis of 37 RCTs following the PRISMA guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

135. Comparison of anlotinib and erlotinib in refractory non-small cell lung cancer: a systematic review and meta-analysis of safety and efficacy

Comparison of anlotinib and erlotinib in refractory non-small cell lung cancer: a systematic review and meta-analysis of safety and efficacy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

136. Comparison of end-of-life care in people with COPD or lung cancer: a systematic review

Comparison of end-of-life care in people with COPD or lung cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

137. Histone deacetylase (HDAC) inhibitors for non-small cell lung cancer: a patient-level meta-analysis

Histone deacetylase (HDAC) inhibitors for non-small cell lung cancer: a patient-level meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

138. Long-term survival of surgically treated synchronous multiple primary lung cancer

Long-term survival of surgically treated synchronous multiple primary lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

139. Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis following the PRISMA guidelines

Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis following the PRISMA guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

140. Meta-analysis of pulmonary resection for metastatic colorectal cancer to the lung

Meta-analysis of pulmonary resection for metastatic colorectal cancer to the lung Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO